ADMA: a specific biomarker for pathologic progress in diabetic microvascular complications?
This study highlights the role of glycated hemoglobin (HbA1c), asymmetric demethylargine (ADMA) and N-ϵ-(carboxymethyl)-lysine (CML) in different periods of progress in Type 2 diabetes, and identifies a pathomechanism-based biomarker that is linked not only to the metabolic progresses but also to the underlying angiopathic progresses. Peripheral blood samples from 100 healthy volunteers, 227 subjects with prediabetes, 173 subjects with Type 2 diabetes and 92 subjects with early diabetic microvascular complications were collected and analyzed for HbA1c, ADMA and CML. Compared to HbA1c and CML, ADMA is the strongest independent predictor and a significantly discriminative receiver operating characteristics profile, clearly distinguishing those with early diabetic microvascular complications. ADMA maybe serve as a pathomechanism-based biomarker, predicting the progression of microvascular complications.